MDASI Ovarian Cancer Module

• Purpose: To assess the severity of multiple symptoms related to ovarian cancer and the impact of these symptoms on daily functioning
• Population: Patients with symptoms caused by ovarian cancer and its treatment
• Assessment areas: Severity of multiple symptoms and the impact of symptoms on daily functioning during the last 24 hours
• Method: Self-report; paper-and-pencil form or tablet PC (self-administered or via interview), or telephone-based interactive voice response (IVR) system
• Time required: Five minutes
• Scoring: Please see the MDASI User's Guide
• Reliability: Cronbach alpha reliability ranges from 0.88 to 0.91

Click on a linked language to view a sample in PDF format.

Don't see a language you need?  Contact us at symptomresearch@mdanderson.org.
 

In response to the FDA's 2009 guidance for the pharmaceutical industry on the use of PRO measures in medical product development to support labeling claims, we have prepared a MDASI User's Guide to document the development and psychometric properties of the MDASI and its modules, including the MDASI-OC. The User Guide addresses the recommendations in the FDA guidance and establishes the MDASI's adequacy as a measure to support medical product claims.

Validation

Williams LA, Agarwal S, Bodurka DC, et al. Capturing the patient's experience: using qualitative methods to develop a measure of patient-reported symptom burden: an example from ovarian cancer. J Pain Symptom Manage 46(6): 837-845, 2013. PMCID: PMC3775907.

Sailors MH, Bodurka DC, Gning I, et al. Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. Gynecol Oncol 130(2): 323-328, 2013. PMCID: PMC3713195.

Cleeland CS, Mendoza TR, Wang XS, et al. Assessing Symptom Distress in Cancer: The M. D. Anderson Symptom Inventory. Cancer 2000; 89:1634-1646.

Clinical Application

Meyer LA, Nick AM, Shi Q, et al. Perioperative trajectory of patient reported symptoms: A pilot study in gynecologic oncology patients. Gynecol Oncol 136(3): 440-445, 3/2015.

Meyer LA, Shi Q, Iniesta MD, et al. Comparison of patient-reported symptom burden in patients with ovarian cancer undergoing primary vs. interval tumor-reductive surgery [abstract]. American Society of Clinical Oncology (ASCO) 53rd Annual Meeting, Chicago IL, Jun 2-6, 2017. J Clin Oncol 35(Suppl), 5/2017; Abstract #5557.

Meyer LA, Lasala J, Cain K, et al. Adoption of an enhanced recovery program leads to decreased patient reported opioid related adverse events [abstract]. International Society for Quality of Life Research (ISOQOL) 23rd Annual Conference, Copenhagen, Denmark, Oct 19-22, 2016. Qual Life Res 25(1 Supplement): 119, 10/2016; Abstract #2043.

Turner M, Monk B, Bodurka DC, et al. Patient-reported symptoms in ovarian cancer before and after disease progression in conjunction with bevacizumab maintenance therapy [abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting, Washington DC, May 21-25, 2016. Value Health 19(3): A158, 5/2016; Abstract #PCN138.

Meyer LA, Nick AN, Iniesta MD, et al Comparison of patient-reported symptom burden pre- and post-implementation of an enhanced recovery pathway for gynecologic surgery [abstract]. World Congress of Enhanced Recovery After Surgery and Perioperative Medicine, Washington DC, May 9-12, 2015. Can J Anesth 62(6): 683, 4/2015; Abstract #OR002.